{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Seroconversion after 1 immunization"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Seroconversion after 2 immunizations"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Seroconversion after 3-4 immunizations"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Humoral immunity was determined by enzyme-linked immunosorbent assay (ELISA) to measure the presence of circulating antibodies to MAGE-A3. Titers against an antigen were considered significant if they were \\>100. Induction of responses was considered significant if there was a change from undetectable (\\<100) to detectable (\\>100) or if there was an at least 4-fold increase in titers over time.","groups":[{"description":"Includes all subjects who received at least 1 immunization with study drug and had a baseline and at least 1 post-baseline immunity assessment.","id":"OG000","title":"Immunogenicity Analysis Set"}],"paramType":"NUMBER","populationDescription":"The Immunogenicity Analysis Set comprises all subjects who received at least 1 immunization with study drug and had a baseline and at least 1 post-baseline immunity assessment.","reportingStatus":"POSTED","timeFrame":"Baseline, first immunization, and first and second leukopheresis prior to auto-SCT; Days 31, 73, 194, 284, and 374 after auto-SCT","title":"Induction or Augmentation of MAGE-A3-Specific Humoral Immunity","type":"SECONDARY","unitOfMeasure":"participants"}